CMMB - What's Going On With Fibro-Inflammatory Disease Focused Chemomab Therapeutics On Tuesday? | Benzinga
Chemomab Therapeutics Ltd (NASDAQ:CMMB) shares are trading on a strong volume session volume of 6.1 million, compared to an average volume of 181.231K, as per the data from Benzinga Pro.
Tuesday, Chemomab Therapeutics announced that the Patent Offices in Brazil and Israel have granted new patents for CM-101.
CM-101 is Chemomab’s first-in-class monoclonal antibody that neutralizes CCL24, a novel disease target shown to play a critical role in the processes that drive diseases involving fibrosis and inflammation.
CM-101 is currently being ...